Peptide LibraryHuman study PLS-00223
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure
Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
Reports of this study
Every publication, registration and abstract describing this one study. Participants are counted once.
- A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failureregistry entry · NCT02388529 (WITHDRAWN, no results posted, planned enrollment 0)
Design and participants
- Design
- Other design
- Population
- Patients with heart failure (planned); no participants were enrolled.
- Conditions
- Heart Failure
- Planned enrollment (registry)
- 0
- Enrolled
- 0
- Randomized
- Not reported
- Completed follow-up
- Not reported
Intervention and comparator
What each group received. Related peptides, analogs and combinations are never treated as the compound itself.
What the authors reported
As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.
Adverse events
None reported. That is not evidence of safety, and how safety was monitored isn’t described.
Peptide Library’s assessment
An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.
Limitations
- other: The registration was withdrawn with an actual enrollment of 0, so no data were ever collected.
- inappropriate population: The planned population was heart failure patients, not people with Barth syndrome or primary mitochondrial myopathy.
- abstract only: Only registry fields are available: no publication, no results and no detailed outcome or design description.
No risk-of-bias assessment has been published for this study’s results.
Claims this study informs
- Improves function in Barth syndrome: not eligible (not primary study) for “Muscle strength, exercise capacity and fatigue”
- Improves exercise capacity in primary mitochondrial myopathy: not eligible (not primary study) for “Six-minute walk distance and fatigue”
- Is safe for human administration: not eligible (not primary study) for “Adverse events, including injection-site reactions, and discontinuations”
Where each value comes from
- arms: NCT NCT02388529, registry (interventions field) · extracted by AI (automated, not verified by a person)
- design: NCT NCT02388529, registry (phases, study_type, status fields) · extracted by AI (automated, not verified by a person)
- limitations: NCT NCT02388529, registry (status and enrollment fields) · extracted by AI (automated, not verified by a person)
- outcomes: NCT NCT02388529, title (study title) · extracted by AI (automated, not verified by a person)
- participants: NCT NCT02388529, registry (enrollment and enrollment_type fields) · extracted by AI (automated, not verified by a person)
- population: NCT NCT02388529, registry (conditions field) · extracted by AI (automated, not verified by a person)
Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.
These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).